Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent ...

- EffiX™ is designed to meet the industry's demand for a high-yield, stable, and non-lysogenic E. coli expression system. It serves as a comprehensive solution for the development and ...

ADMA Biologics’ EPS of $0.46 beat the forecast by over 200%. Total revenue for Q4 2024 grew by 59% year-over-year. The stock increased by 4.23% in after-hours trading. The company provided a ...

FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA (1) of $ ...

Four years after Sanofi shelled out $125 million for global rights to Biond Biologics’ novel immune checkpoint inhibitor, the French pharma is handing the prospect back to Biond. The move is due ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window SAN DIEGO ...

Operating income decreased by 11.4% to €2.6 million from €3.0 million over the period. This €0.3 million decrease is primarily attributable to the €0.6 million decrease in the research tax credit ...